中創環球(01678.HK)與寶帝來簽訂諒解備忘錄
格隆匯12月13日丨中創環球(01678.HK)發佈公吿,2021年12月13日,公司與香港寶帝來控股集團有限公司簽訂諒解備忘錄,形成策略聯盟。根據該協議,該關係的實質、具體合作的條款和條件仍在談判中,其聯盟的形式包括但不限於成立共有公司、建立控股公司和附屬關係等。
根據披露,寶帝來在香港成立,與其關聯公司包括深圳市寶帝來投資實業有限公司和深圳寶帝來科技有限公司,主要從事各種生產業務的機器人和機械的設計和製做。寶帝來集團在全球擁有約260家銷售辦事處或代表。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.